Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb, 2seventy bio fell early Monday as FDA said it would miss a regulatory action date on a cancer treatment
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.